Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee

  • Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Markt vandaag Koersen Forum Premium IEX Expert
Home  /  Forum  /  Amerikaanse aandelen  /  Repros Therapeutics Inc. (Public, NASDAQ:RPRX

Amerikaanse aandelen« Terug naar discussie overzicht

Repros Therapeutics Inc. (Public, NASDAQ:RPRX

Volgen
241 Posts
Pagina: «« 1 ... 8 9 10 11 12 13 »» | Laatste | Omlaag ↓
  16. Demenkovets 2 september 2010 19:44
    quote:

    roos1971 schreef:

    [quote=Demenkovets]
    [quote=roos1971]
    o jee en hij lijkt toch werder te willen schieten...

    en ik moet zo weg... meneer demen???

    ;-)

    grapje.. ik zie het vanavond wel ;-)
    [/quote]

    op 3 dollar sms ik wel ;-)
    [/quote]

    jaaaaaaaaaaaaaaaa daar mag u me zelfs voor wakker bellen!!! ;-)
    Dan hoop ik voor u dat ik het niet gedroomd heb ;-)
  18. Demenkovets 23 december 2010 18:44
    Repros® Therapeutics Submits Data to the FDA Supporting Morning Assessment of Testosterone for Men Treated with Androxal® as Indicative of Average and Maximum Levels Attained

    Typically 24 hour assessment is required in studies of testosterone replacement therapies

    Press Release Source: Repros Therapeutics Inc. On Thursday December 23, 2010, 11:02 am EST

    THE WOODLANDS, Texas--(BUSINESS WIRE)-- Repros Therapeutics Inc.® (NasdaqCM:RPRX) today announced it has submitted to the FDA data collected from three different studies which the Company believes demonstrates that the assessment of testosterone levels between 8 and 10 in the morning is indicative of the maximum and average levels of the male hormone achieved during a particular day following the administration of Androxal®. In the Type B meeting held on November 8, 2010, and reported in the Company’s press release of November 9, 2010, the FDA stated the preferred method to determine testosterone levels in treatments designed to replace the hormone is a 24 hour assessment.

    Repros used the services of an outside statistician, Dr. Richard Trout, Professor Emeritus, Rutgers University, in arriving at the conclusions it has reached.

    The Company has conducted three trials in which serial testosterone measurements were made over a 24 hour period. Two of the studies assessed 14 (ZA-002) and 11 (ZA-003 subset) time points over the 24 hour period in a total of 28 subjects. A third study (ZN-018) obtained measurements at six points in a total of 20 subjects.

    Using the data from the 002 and 003 studies the sponsor has determined that a single total testosterone assessment made between 8 and 10 in the morning correlates to the average of the values of the testosterone measurements for a given subject on a given day (correlation coefficient roughly 0.9 for the times 8, 9 and 10, p value < 0.001).

    Performing the same assessment for the maximum value of total testosterone recorded in a 24 hour period, the same single total testosterone assessment made between 8 and 10 in the morning correlates to the maximum value of testosterone for a given subject on a given day (correlation coefficient roughly 0.9 for the times 8, 9 and 10, p value < 0.001).

    From the 018 study that assessed men at baseline and after 14 days of treatment, the Company observed that Androxal raises each time point testosterone level by an average of 200 ng/dl at 12.5 mg and 260 ng/dl at a 25 mg dose.

    Unlike topical testosterone preparations, Androxal maintains the normal daily rhythm of testicular testosterone production with peak levels generally occurring in the morning and trough levels exhibited in the evening. The testosterone levels achieved by the administration of topical preparations are a function of a variety of factors none of which relate to the normal daily rhythm. In some instances, subject to subject variability can lead to supernormal levels of testosterone several hours after administration of the topical preparations. The Company has committed to conduct one additional 24 hour study to show that Androxal’s action in maintaining the normal rhythm is both predictable and dose dependent.

    +42%.
241 Posts
Pagina: «« 1 ... 8 9 10 11 12 13 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
Sif Holding 14,520 +0,20 +1,40%
Eurocommercial Properties 25,550 +0,25 +0,99%
ABN AMRO BANK N.V. 16,385 +0,14 +0,83%
Vastned 23,950 +0,15 +0,63%
Wereldhave 14,820 +0,08 +0,54%
KPN 3,626 +0,02 +0,53%
DSM FIRMENICH AG 116,450 +0,45 +0,39%
RELX 43,120 +0,02 +0,05%
ING 16,688 +0,01 +0,04%
UNILEVER PLC 57,780 +0,02 +0,03%
AZERION 1,580 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
JDE PEET'S 18,500 -1,56 -7,78%
Alfen N.V. 12,185 -0,77 -5,94%
Sligro 12,420 -0,78 -5,91%
ASMI 561,800 -29,40 -4,97%
BESI 111,600 -5,35 -4,57%
AMG Critical Materials N.V. 15,880 -0,74 -4,45%
ALLFUNDS GROUP 5,270 -0,24 -4,27%
ASML 716,700 -31,20 -4,17%
SIGNIFY NV 20,540 -0,84 -3,93%
AALBERTS NV 34,920 -1,26 -3,48%
FASTNED 18,300 -0,66 -3,48%
Kendrion 11,860 -0,40 -3,26%
Pharming 0,686 -0,02 -3,04%
Akzo Nobel 58,300 -1,72 -2,87%
TKH 36,920 -1,02 -2,69%
TomTom 5,190 -0,13 -2,35%
Vopak 40,980 -0,96 -2,29%
PostNL 1,204 -0,03 -2,27%
Heineken 79,260 -1,80 -2,22%
JUST EAT TAKEAWAY 12,630 -0,27 -2,13%
AMX 882,35 -18,89 -2,10%
Flow Traders 17,890 -0,38 -2,08%
Brunel 8,620 -0,18 -2,05%
HEIJMANS KON 24,150 -0,50 -2,03%
Galapagos 26,380 -0,54 -2,01%
OCI 26,180 -0,52 -1,95%
NX FILTRATION 4,415 -0,09 -1,89%
ArcelorMittal 21,490 -0,41 -1,87%
IMCD 152,500 -2,90 -1,87%
EXOR NV 97,450 -1,85 -1,86%
INPOST 17,100 -0,32 -1,84%
Basic-Fit 22,300 -0,36 -1,59%
B&S Group SA 4,670 -0,07 -1,48%
UMG 22,750 -0,32 -1,39%
RANDSTAD NV 44,000 -0,61 -1,37%
Philips Koninklijke 27,440 -0,37 -1,33%
Accsys 0,622 -0,01 -1,27%
ASCX 1.198,49 -14,88 -1,23%
SHELL PLC 30,800 -0,38 -1,22%
AEX 897,55 -10,87 -1,20%
EBUSCO HOLDING 0,786 -0,01 -1,19%
PROSUS 33,665 -0,40 -1,17%
WDP 24,120 -0,28 -1,15%
THEON INTERNAT 10,700 -0,12 -1,11%
Nedap N.V. 56,600 -0,60 -1,05%
Arcadis 63,400 -0,65 -1,01%
Corbion 23,580 -0,24 -1,01%
CTP 16,300 -0,16 -0,97%
Fugro 20,940 -0,20 -0,95%
ADYEN NV 1.383,800 -12,40 -0,89%
ASR Nederland 43,440 -0,36 -0,82%
ACOMO 17,420 -0,14 -0,80%
ForFarmers 3,155 -0,03 -0,79%
Air France-KLM 8,828 -0,06 -0,72%
RENEWI 7,650 -0,05 -0,65%
Aperam 24,640 -0,16 -0,65%
Fagron 18,680 -0,10 -0,53%
Avantium 1,870 -0,01 -0,53%
Aegon 5,610 -0,02 -0,43%
Wolters Kluwer 155,650 -0,65 -0,42%
Van Lanschot Kempen NV 42,500 -0,15 -0,35%
Ahold Delhaize 30,470 -0,09 -0,29%
NSI 20,850 -0,05 -0,24%
BAM 3,804 -0,01 -0,21%
CM.COM 6,560 -0,01 -0,15%
SBM Offshore 16,490 -0,02 -0,12%
NN Group 44,940 -0,02 -0,04%
vlag naam koers verschil relatief verschil
AEX 897,55 -10,87 -1,20%
AEX GR 3.507,35 -42,49 -1,20%
Germany40^ 18.741,30 -261,08 -1,37%
FTSE 100 8.229,99 -98,73 -1,19%
EURO50 4.873,21 0,00 0,00%
US30^ 42.066,00 0,00 0,00%
Nasd100^ 19.794,40 0,00 0,00%
US500^ 5.702,78 0,00 0,00%
Japan225^ 38.215,90 0,00 0,00%
VD-NEW 15,08 +0,88 +6,20%
#/^ Index indications calculated real time, zie disclaimer